ARMR Sciences

ARMR Sciences Inc.

0 Investors

Biodefense Technology, Biotechnology

NEW YORK, NY

ARMR Sciences Inc. is a biodefense technology startup developing countermeasures against synthetic drug threats, with a primary focus on fentanyl. The company is pioneering a preventative immunotherapy, ARMR-100, designed to provide pre-exposure protection against overdoses, shifting the national security and public health approach from reaction to prevention.

Products & Team

ARMR-100

Preventive ImmunotherapySeed

ARMR-100 is a long-acting, preventive immunotherapy intended to provide annual protection against illicit fentanyl overdoses. Originally developed at the University of Houston, this investigational treatment is designed to function as a pre-exposure countermeasure, stopping the drug from affecting the user.

Value Proposition

ARMR-100 addresses the risk of fatal fentanyl overdose by providing a proactive layer of protection. It aims to prevent overdoses before they occur, offering a safety net for individuals at high risk of occupational exposure or for vulnerable civilian populations.

Pain Points

The primary problem addressed for military and first responders is the constant threat of accidental, and potentially fatal, exposure to fentanyl in the line of duty. For the civilian market, it addresses the widespread fear and reality of both intentional and unintentional overdoses.

Functions as a pre-exposure preventative measureDesigned to provide long-acting, annual protectionAnimal studies showed it prevents approximately 92% of fentanyl from entering the brainAchieved 100% blockage of fentanyl's effects in animal studies